Author:
Shovlin C.L.,Buscarini E.,Sabbà C.,Mager H.J.,Kjeldsen A.D.,Pagella F.,Sure U.,Ugolini S.,Torring P.M.,Suppressa P.,Rennie C.,Post M.C.,Patel M.C.,Nielsen T.H.,Manfredi G.,Lenato G.M.,Lefroy D.,Kariholu U.,Jones B.,Fialla A.D.,Eker O.F.,Dupuis O.,Droege F.,Coote N.,Boccardi E.,Alsafi A.,Alicante S.,Dupuis-Girod S.
Subject
Genetics (clinical),Genetics,General Medicine
Reference53 articles.
1. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study;Al-Samkari;Haematologica,2020
2. Epidemiological investigation of Rendu-Osler disease in France: its geographical distribution and prevalence;Bideau;Population,1989
3. Cerebral abscess associated with odontogenic bacteremias, hypoxemia, and iron loading in immunocompetent patients with right-to-left shunting through pulmonary arteriovenous malformations;Boother;Clin. Infect. Dis.,2017
4. International similarities and differences in hereditary hemorrhagic telangiectasia (HHT) pathways reported by patients and clinicians;Boother;Thorax,2019
5. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia;Buscarini;Orphanet J. Rare Dis.,2019